SBIR Phase I:De novo assays for detection of the proteolytic activity in botulinum neurotoxin-based pharmaceuticals

Award Information
Agency:
National Science Foundation
Branch
n/a
Amount:
$150,000.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1013945
Award Id:
99105
Agency Tracking Number:
1013945
Solicitation Year:
n/a
Solicitation Topic Code:
BT5
Solicitation Number:
n/a
Small Business Information
1568 Luneta Drive, Del Mar, CA, 92014
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
199748000
Principal Investigator:
WardTucker
DPhil
(608) 441-8172
wtucker@biosentinelpharma.com
Business Contact:
WardTucker
DPhil
(608) 441-8172
wtucker@biosentinelpharma.com
Research Institute:
n/a
Abstract
This Small Business Innovation Research (SBIR) Phase I project proposes to develop a universal, in vitro assay for determining the enzymatic activity of botulinum neurotoxin (BoNT)-based pharmaceuticals. BoNTs are used in many cosmetic and pharmaceutical applications due to their long lasting effects and specificity for motor neurons. Currently, the strength and quality of BoNT-based pharmaceuticals is assessed using a mouse bioassay where BoNT is injected into mice and a unit of activity depends on the rate or proportion of deaths. Beyond animal testing concerns, the mouse bioassay's inaccuracy and the lack of standardized protocols among manufacturers put patient safety and clinical outcomes at risk. The proposed technology will reduce animal use and provide a method to uniformly assess the activity of BoNT-based pharmaceuticals regardless of manufacturer, thus increasing patient safety and the likelihood of successful treatment. The broader/commercial impacts of this research are increased patient safety, reduced animal testing, and the potential to enable point-of-use/point-of-care testing. The proposed technology could be used for decontamination testing at manufacturing sites, authenticity (against counterfeit drugs) testing at border control points, and in-office testing for high-dose procedures where toxin concentration is critical for clinical outcomes. The proposed technology would be the first of its kind on the commercial market. Other commercially available assays are not suitable for assessing BoNT-based pharmaceuticals because formulation stabilizers interfere with the assays. The proposed technology could be further adapted for testing BoNT activity in highly complex matrices extending the technology's utility into food, water, biodefense, and environmental testing.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government